Viewing Study NCT06027268

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:39 PM
Ignite Modification Date: 2026-02-07 @ 3:52 AM
Study NCT ID: NCT06027268
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-17
First Post: 2023-08-31
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Sponsor: Wake Forest University Health Sciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Triple-Negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast-Female View
None Breast-Male View
None Triple-Negative Breast Cancer View
None Metastatic View
None Locally advanced unresectable View